REKA Health’s Solutions Deployed by Britain’s Largest ECG Interpretation Service Provider Broomwell-Healthwatch

— Broomwell-Healthwatch will deploy the REKA E100L (CE Mark) to serve the UK Market

— REKA’s solution was chosen for its intuitiveness and capability to enable immediate analysis and results interpretation

MANCHESTER, England, March 16, 2015 /PRNewswire/ — Britain’s largest electrocardiogram interpretation service Broomwell-Healthwatch Ltd (“Broomwell”) has deployed Singapore-based REKA Health Pte Ltd’s (“REKA”) cardiac monitors and solutions to serve the UK National Health Service Primary Care and private market to detect arrhythmia.

Broomwell currently offers mobile ECG recorder units for patients to wear 24-hours a day up to eight days and is expanding its arrhythmia detection offerings to include the E100L Digital Loop Event Monitor by REKA.

Episodes of arrhythmia, a heart condition whereby the heartbeat is irregular, can occur anytime, lasting between a few minutes to hours. The Digital Loop Event Monitor service is a seven-day home monitoring service, offered by Broomwell, to record the ECG of a patient that is experiencing arrhythmia.

The REKA E100L — whose small size gives mobility allowing users to use it anytime — can record valuable data before and after an arrhythmia episode. The data is uploaded onto REKA’s cloud solution, providing cardiac-physiologists with insights.

Broomwell is deploying REKA’s solution to enhance the operational efficiency of its cardiac professionals. Patients can also use a computer or mobile application to upload ECG recordings, which can be immediately interpreted.

Joshua Rowe, Broomwell’s Chairman, said, “REKA’s solution equips us to expand our services for arrhythmia. The monitoring will be greatly enhanced by the intuitiveness and availability of data via REKA’s system.  Immediate analysis and interpretation of results by Broomwell’s expert cardiac clinicians is now possible.”

Tan Kae Yuan, REKA’s CEO, said, “With REKA’s solution being deployed to serve the UK market, our CE Mark E100L can benefit more heart patients while reducing the healthcare cost burden.”

About Broomwell-Healthwatch
Broomwell, set up in 2004, enables 12 lead ECG diagnostics via the telephone or computer, providing expert cardiac diagnostics within minutes. Broomwell does about 3,000 ECGs per week and is available to assist medical facilities daily.   


About REKA
REKA, founded in 2011, is a leading digital cardiovascular monitoring solution provider for the healthcare industry. REKA has intuitive solutions, which integrates devices and Cloud-based software compliant with medical regulations. REKA is headquartered in Singapore with offices in USA and Europe.  

WeR1 Consultants
Benjamin Cher

Mondia Media Presented “Mondia Mix” Streaming App in Partnership With Universal Music

HAMBURG, Germany, March 9, 2015 /PRNewswire/ — Mondia Media presented “Mondia Mix” at the Mobile World Congress 2015, as part of the Mobile Connect initiative, from the GSMA, and in partnership with Universal Music, who provided the content exclusively for the showcase, curated by “DIGSTER”.


Mondia Mix” is a music streaming playlist application for iOS and Android smartphones. Based on a subscription service, users can stream playlists and select tracks for offline usage, whilst keeping music right holders protected and minimizing data costs.

Offered as a white label service, “Mondia Mix” is set-up and adjusted to each customer’s market in a few days. Subscription prices and cycles are independent from features, allowing customers to select the most effective consumer proposition. The content catalogue and editorial choices are managed through a dedicated CMS. Customers can even develop their independent front ends, using Mondia Media’s Music API.

Mondia Mix” is targeted at mobile operators wanting to launch an entry level, high quality music streaming application. Using mobile operator authentication and billing, it integrates with operator’s core services in a seamless manner.

Mondia Media will carry on using Mobile Connect as a means of having a unified authentication mechanism for its mobile operator services, as is the case of “Mondia Mix“.

About Mondia Media

As a leading independent digital entertainment enabler, we create and operate digital entertainment solutions for our partners across the globe, ranging from telecom operators and hardware manufacturers, to media companies and broadcasters.

With the “Mondia Media Entertainment Universe”, we established a convergent all-in-one solution at a high level of technological expertise. We offer our partners the services of managing, distributing and billing the entire portfolio of entertainment content from a single platform.

HOOQ, Asia’s Video-on-Demand Service, Debuts in the Philippines in Partnership With Globe Telecom

HOOQ offers over 10,000 blockbuster movies & TV series

MANILA, Philippines, Feb. 9, 2015 /PRNewswire/ — Just one week after its establishment, HOOQ, Asia’s video-on-demand service, announced that it will kick off in the Philippines from late February in partnership with Globe Telecom.

Filipinos first in Asia to get access to extensive Hollywood and local content with Globe Telecom and HOOQ

Filipinos first in Asia to get access to extensive Hollywood and local content with Globe Telecom and HOOQ

HOOQ, a start-up joint venture between Singtel, Sony Pictures Television and Warner Bros. Entertainment, will enable customers of Globe Telecom to enjoy unlimited online streaming access and an offline viewing option to top Hollywood and Filipino movie and television content, via any device including computers, smartphones and tablets.

Extensive Hollywood and local content

Filipinos can look forward to more than 10,000 movies and television episodes and TV shows including titles from partners Sony and Warner Bros. Customers can watch Hollywood movies such as Harry Potter, Spider-Man and Inception, while enjoying popular TV series such as Gossip Girl, Friends and Smallville.

Local film and TV content will also be available through partnerships with the country’s top studios, such as GMA, Viva Communications, Regal Entertainment, and ABS-CBN.  Customers can watch local high-grossing films such as Metro Manila, A Secret Affair, Shake Rattle and Roll and Ang Tanging Ina, as well as classics including Dyesebel, Bagets and Bituing Walang Ningning. Highly-rated TV shows like My Husband’s Lover, Mulawin, Tayong Dalawa and Mara Clara will also be available anytime and anywhere.

“Across the emerging economies, people have amazing stories and love stories. However, a few billion people have no quality way of seeing the best stories from Hollywood or their local market.  HOOQ will change that.  HOOQ will change the way people in emerging markets consume and enjoy entertainment,” said HOOQ Chief Executive Officer, Mr. Peter G. Bithos. “The Philippines is a natural first market for us. Filipinos’ dual love of local and Hollywood content combined with their  digital savviness makes the Philippines a perfect place for us to start,” he added.

The former Globe Telecom Chief Operating Advisor, Mr Bithos also announced its first distribution partnership. “Our partnership with Globe Telecom, the leader in digital partnerships in the Philippines, helps us bring Philippine customers a premium video service and new form of entertainment that combines the best of Hollywood, Asian and Philippine video content across all devices,” Mr Bithos said.

Globe Telecom’s customers first to get HOOQ at P199 per month

According to a Nielsen report in 2014, viewing online video content has become a pastime for digital consumers in the Philippines, with 85% watching at least weekly, the second highest in the region. The same report also revealed that 7 in 10 digital consumers in the country report watching TV content and movies via online sources such as video-on-demand, the second highest penetration of internet TV in the region at 71%.

“Now more than ever, Filipinos consider connectivity as an essential part of their daily lives. Our customers, whether prepaid, postpaid, or broadband, are increasingly embracing an always-on world where they expect a wonderful experience from innovative and engaging data and content offers. Right now, we are in the best position to offer this type of service as the leader in enabling the digital lifestyle of Filipinos and the number one network for smartphones. To meet their needs, we see the video-on-demand services offered by HOOQ as a critical offering representing the future of the industry. Now that consumers have access to a variety of international and local content, entertainment will now be more personal, and with Globe, this means experiencing it with the highest quality,” said Mr. Ernest Cu, President and CEO of Globe Telecom. 

Recognising the value that video-on-demand services deliver to consumers, Globe Telecom will provide its customers with the ability to download HOOQ, which will soon be available to customers on a plan-based service for Philippine Peso 199 per month for access to thousands of movies, far more affordable than buying a ticket for just one movie. It will also be offered as a bundled service with the telco’s GoSURF and Tattoo broadband services.

HOOQ enhances digital lifestyles

“Following the launch in the Philippines, HOOQ will be rolled out across Asia soon. The rapid adoption of connected devices means more people in Asia are able to access the Internet anywhere and at any time, driving demand for compelling content that enhances their digital lives,” said Mr Jonathan Auerbach, Singtel CEO Group Digital Life. “HOOQ is set to change the way people across the region consume and enjoy entertainment.”

Mr. George Chien, Executive Vice President, Networks at Sony Pictures Television, said: “We share the excitement of offering entertainment fans across Asia access to high quality video services directly to their mobile devices. HOOQ provides a unique combination of Hollywood and local favorites while providing a high-quality viewing experience they’ve come to expect in today’s digital world.”

Mr. Anuraj Goonetilleke, Vice President Corporate Business Development and Strategy at Warner Bros. Digital Distribution said: “We’re very excited about the launch of our joint video-on-demand business across Asia, starting with the Philippines.  Providing world-class content to Asia’s entertainment fans will meet a voracious appetite for new and classic videos and TV episodes on-demand.”

The service will also be accessible to all customers in the Philippines through its website — Through, customers can watch videos of their choice and pay for the subscription by credit card.

About HOOQ
HOOQ is a regional video-on-demand subscription service by Singtel, Sony and Warner Bros. HOOQ will deliver over 10,000 Hollywood blockbusters and popular local programmes to customers anytime, anywhere by enabling them to stream and download their favourite shows on their device or platform of choice. For more information, visit

About Globe Telecom
Globe Telecom is a leading full service telecommunications company in the Philippines, serving the needs of consumers and businesses across an entire suite of products and services including mobile, fixed, broadband, data connections, internet and managed services.  Its principals are Ayala Corporation and Singtel who are acknowledged industry leaders in the country and in the region.  For more information, visit  Follow Globe Telecom on Facebook at and Tatoo at as well as on Twitter @enjoyglobe and @choosetattoo and Instagram at @enjoyglobe and @choosetattoo.

About Singtel
Singtel is Asia’s leading communications group providing a portfolio of services including voice and data solutions over fixed, wireless and Internet platforms as well as infocomm technology and pay TV. The Group has presence in Asia and Africa with over 500 million mobile customers in 25 countries, including Bangladesh, India, Indonesia, the Philippines and Thailand. It also has a vast network of offices throughout Asia Pacific, Europe and the United States.

About Sony Pictures Entertainment
Sony Pictures Entertainment (SPE) is a subsidiary of Sony Entertainment Inc., a subsidiary of Tokyo-based Sony Corporation. SPE’s global operations encompass motion picture production, acquisition and distribution; television production, acquisition and distribution; television networks; digital content creation and distribution; operation of studio facilities; and development of new entertainment products, services and technologies. For additional information, go to

About Warner Bros. Entertainment
Warner Bros. Entertainment Inc. is a global leader in all forms of entertainment and their related businesses across all current and emerging media and platforms. A Time Warner Company, the fully integrated, broad-based studio is home to one of the most successful collections of brands in the world and stands at the forefront of every aspect of the entertainment industry from feature film, television and home entertainment production and worldwide distribution to DVD, digital distribution, animation, comic books, video games, product and brand licensing, and broadcasting.

Photo –

China Cord Blood Corporation and Cord Blood Registry Enter Into Strategic Collaboration

HONG KONG, Jan. 28, 2015 /PRNewswire/ – China Cord Blood Corporation (CCBC, NYSE: CO), China’s first and largest umbilical cord blood bank, and Cord Blood Registry® (CBR®), the world’s largest newborn stem cell company, today entered into a memorandum of understanding regarding their strategic collaboration in China and the United States. The two prominent cord blood banks will share data on cord blood collection, processing and storage to advance international standards. The companies will also work together under the memorandum, to develop a family disease registry for CCBC’s clients in China and jointly support newborn stem cell-related clinical trials in the U.S. and China.

This important collaborative effort achieves a milestone in bringing the two largest cord blood banks in the world into close concert for the benefit of their client families, future patients and the stem cell clinical research community. It also presents an opportunity to aid families impacted by certain diseases across an international and racially diverse population. In the aggregate, the two companies have collected and stored samples from an estimated 1 million newborn children worldwide, accounting for nearly half of all cord blood units preserved globally.

“CBR and CCBC are both committed to bringing forward clinical applications of newborn stem cells for a host of conditions that could benefit from regenerative medicine,” said Geoffrey Crouse, President and Chief Executive Officer of CBR. “Through this collaboration, we will be able to share our expertise and resources and improve mutual access to crucial research in China and the U.S. This first of its kind partnership is a significant step toward raising global awareness of the importance of newborn cord blood hematopoietic stem cell research.”

Kam Yuen, Chairman of CCBC commented, “This memorandum brings together two cord blood banks that collectively serve approximately 1 million clients and represents the most significant joint effort to date in the global cord blood banking industry. Through this collaboration, we hope to create new possibilities to service clients and patients, and provide greater support to the stem cell clinical research communities in both China and the U.S.”

About China Cord Blood Corporation

China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at

About Cord Blood Registry

Cord Blood Registry® (CBR®) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing more than 500,000 cord blood and cord tissue units. CBR is dedicated to advancing the clinical application of newborn stem cells by partnering with leading research institutions to design and conduct FDA-regulated clinical trials for conditions that have no cure today. For more information, visit

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, performance and results of operations, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in the filings from time to time with the U.S. Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Information:

China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180

ICR, Inc.
William Zima
China Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185

Cord Blood Registry
Tina Amirkiai
Tel: +1 (415) 318-4262

BioXcel Initiates Rare Disease Project with Alexion Utilizing Big Data Innovation Lab

– Project aims to support development of transformative treatment options

BRANFORD, Connecticut, Jan. 28, 2015 /PRNewswire/ — BioXcel Corporation, a global leader in providing cloud-based pharma big data solutions for discovering novel products, announced today the initiation of a big data project with Alexion to characterize and prioritize pertinent sets of rare diseases for relevant therapeutic modalities. Alexion, a biopharmaceutical company focused on delivering life-transforming therapies to serve patients with severe and life threatening disorders, will utilize BioXcel’s first-in-class Big Data Innovation Lab. This state of the art lab applies recursive mapping and big data algorithms by leveraging PharmGPS™ Orphan Disease Suite, Integrated Center of Xcellence housing multidisciplinary teams, and deep domain expertise for deciphering rare disease treatments.

Logo –

“We are pleased to work with Alexion and utilize our expertise and experience to support the development of novel treatment options for patients with rare diseases,” said Vimal Mehta, Ph.D., Chief Executive Officer and Chairman of BioXcel. “Our vision is to maximize the drug discovery capabilities of BioXcel’s Big Data Innovation Lab for developing breakthrough treatments by partnering with leaders such as Alexion.”

PharmGPS™ Orphan Disease Suite
BioXcel’s proprietary Orphan Disease Suite encompasses more than 9,000 rare & ultra-rare diseases, 4,000 -5,000 associated genes, 1,500 disease pathways, and distinct target-indication tiles for antibody, protein, RNA, small molecule and gene therapy modalities. A live multi-dimensional platform enables partners to make informed decisions for a rare disease indication and the associated ideal mode of pharmacotherapy with parameters that include strategic, medical, scientific and commercial aspects. The suite enables the discovery, development, and commercialization of orphan drugs based on disease severity, gene ontology, disease pathways, proteinopathy, standard of care, emerging innovation, enabling technologies, and current drug pipeline – all of which are crucial when addressing the high unmet need of patients with rare and ultra rare diseases.

About BioXcel
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking for pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages a live analytics platform – PharmGPS™, an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams, and an expert council that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel’s global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.

BioXcel Corporation
Anita Ganjoo
Corporate Communications
Tel: 203 273 8388

Photo –

China Foreign Trade Centre (Group) and Reed Exhibitions Sign Strategic Alliance Agreement

SHANGHAI, Jan. 13, 2015 /PRNewswire/ — The China Foreign Trade Centre (Group) and Reed Exhibitions held a signing ceremony and press conference to honor their new strategic alliance agreement and partnership at the Renaissance Shanghai Yangtze Hotel.

This is the first-ever strategic partnership of its kind between Reed, the world’s leading events organizer and China Foreign Trade Centre (Group), a national state-owned, large scale enterprise and the world’s largest exhibition venue provider.

Wang Zhiping, Chairman of China Foreign Trade Centre (Group) and Mike Rusbridge, Chairman of Reed Exhibitions, were in attendance and signed the agreement on behalf of their enterprises.

Chairman Wang Zhiping noted in his address, “As the benchmarking enterprise of China’s convention and exhibition industry with over 50 years in the field, the China Foreign Trade Centre (Group) has accumulated vast experience from organizing and presenting many of the world’s top exhibitions, namely the Canton Fair and mega events such as China International Furniture Fair (Guangzhou), International Building & Construction Trade Fair and International Automobile Industry Exhibition. In the meanwhile, we have additionally modernized two major exhibition venues, the Guangzhou International Convention and Exhibition Centre (Pazhou Complex) and the National Exhibition and Convention Centre (Shanghai Hongqiao). Prior to the completion of the National Exhibition and Convention (Shanghai Hongqiao), the world’s largest exhibition hall in March 2015, these two venues spanned a combined building area of 2.6 million sqm with 738,000 sqm of indoor exhibition space and 143,6000 sqm of outdoor venues. It has been predicted that, in 2015, the total exhibition area of these two venues will exceed 10 million sqm, occupying one tenth of the total exhibition area in China.”

Mike Rusbridge shared his enthusiasm, “After more than two decades of rapid growth in China, today’s signing event is a milestone for Reed Exhibitions. The new strategic alliance agreement between Reed Exhibitions and the China Foreign Trade Centre is ‘a powerful statement of intent’ between two strong partners with one common goal: to continue building world-leading exhibition events in China. Reed’s commitment to China has never been stronger, with our eight outstanding member companies who currently organize 53 events covering 11 specialized industries nationwide. Globally, Reed Exhibitions has brought together over seven million event participants from around the world generating billions of dollars in business for its customers. This new partnership will prove mutually beneficial in the joint projects that we intend to undertake together in China. This alliance will remain instrumental to the modernization and sustained success of the industry.”

Both parties view this new strategic alliance as a “rewarding relationship, long-term cooperation and joint development,” with an aim to not only realize mutual benefits, but to leverage their resources to achieve comprehensive cooperation and joint development in all levels and areas of the exhibition field.

The alliance includes regular executive meetings, resource sharing, professional talent cultivation, exhibition projects, organization and venue cooperation. In May 2015, three mega medical and healthcare industry events, CMEF, API China and PHARM China, organized by Reed Sinopharm, will co-locate for the first time at the National Exhibition and Convention Centre in Shanghai.

The Chinese Government is actively exploring opportunities that can be gained through strategic collaborations. This powerful partnership between China Foreign Trade Centre (Group) and Reed Exhibitions is a pivotal example of domestic and foreign exhibition enterprises combining their strengths and collaborating to create a win-win alliance.

It also signifies a desire to expand and open-up the economy by engaging global players and developing the Chinese convention and exhibition industry, from a large scale market to a cutting edge industry, whilst encouraging strategic growth.

About China Foreign Trade Centre (Group)

China Foreign Trade Centre (CFTC), a government-sponsored institution which affiliated to Ministry of Commerce of PRC, has been responsible for organizing China Import and Export Fair (also known as the Canton Fair) since the establishment of Canton Fair in 1957. And it also hosts or organizes various kinds of exhibitions, expo and business conferences besides running Canton Fair, such as China (Guangzhou) International Furniture Expo, China (Guangzhou) Automobile Exhibition, China Import & Export Commodities Exhibition (Malaysia) etc. At the meantime, CFTC boasts for having and operating a modern Canton Fair complex in Pazhou Island of Haizhu District which occupies the biggest in Asia and the forefront position in the world in term of complex size. Moreover CFTC plays a dominant role in China’s exhibition industry for its professional exhibition experience and service as well as outstanding performance over more than 50 years.

China Foreign Trade Centre (Group), a business entity that affiliated to China Foreign Trade Centre, mainly conducts all forms of exhibitions, including foreign exhibitions in China and Chinese exhibitions both at home and abroad, and also covers business such as advertising, import and export, tourism, hotel, restaurant and property etc., which enables us to provide all-around way services to our customers.

About Reed Exhibitions

Reed Exhibitions is the world’s leading events organizer, with over 500 events in 43 countries. In 2014 Reed brought together over seven million active event participants from around the world generating billions of dollars in business. Today Reed events are held throughout the Americas, Europe, the Middle East, Asia Pacific and Africa and organized by 41 fully staffed offices. Reed Exhibitions serves 43 industry sectors with trade and consumer events and is part of Reed Elsevier Group, a world leading provider of professional information solutions and a FTSE–100 company.  

KT and Ubitus Join Hands to Accelerate Cloud Gaming Service on IPTVs in Korea

TAIPEI and SEOUL, South Korea, Jan. 7, 2015 /PRNewswire/ — Ubitus Inc., the worldwide cloud gaming leader, and KT Corporation, the largest telecommunication service provider in South Korean, are excited to announce their partnership in cloud gaming service today.

KT Corporation has launched its gaming service “Wizgame” on IPTV Set-top-box and plans to strengthen the service by extending game line up in this year. With the collaboration with Ubitus, more blockbuster game titles from leading game companies worldwide will be expected to land on KT’s “Wizgame” going forward. Users will be able to download the updated app in KT’s Appstore from April.

Moreover, KT’s HTML5 Set-top-box devices (three to five models) will be upgraded to support cloud gaming by April, which would enable 60%~70% of existing KT IPTV 5 million subscribers to access cloud gaming service. Ubitus is also aimed to support as many set-top-box devices as possible to expand the device coverage. By the end of this year, 80%~90% subscribers would be able to enjoy cloud gaming service.

Powered by Ubitus’ GameCloud ® solution, KT’s set-top boxes can deliver instant console gaming experiences on demand without the need for users to equip with expensive high-end computers or game consoles as prerequisites. Users will be amazed by the incredible console-level gaming experience, similar to that of PS4 or Xbox, streaming down via their home broadband connections from the cloud.

“Ubitus is thrilled to collaborate with KT and bring ‘Wizgame’ cloud gaming service to the next level in Korea market. We are devoted to enhance customers’ satisfaction by bringing more attractive services and contents to users,” said Wesley Kuo, CEO of Ubitus.

About Ubitus Inc.

Ubitus Inc. has the world’s leading game virtualization technology and cloud-streaming platform. It strives to provide a more pervasive gaming user experience using top-notch technology, allowing players to play the best games at any time and any place as long as they are connected to the internet. The services are compatible across devices, platforms, and networks. It doesn’t matter if the player is using a smart phone, tablet, PC, or smart TV.

As one of the leaders in cloud gaming technology and game streaming services, Ubitus has entered into long-term partnerships with top-notch international game developers, becoming the agent for many classic gaming masterpieces. It has penetrated the Japanese, Korean, US, Hong Kong, and mainland Chinese market. It has liaised with leading telecom service providers, online service providers, and game makers everywhere to provide services to local gamers.

The company was established in 2007, headquartered in Taipei, Taiwan. It currently has 140 employees, and has offices in the US, Japan, South Korea, and Mainland China. Since it was established, it has been generating record-breaking achievements in the global cloud gaming market and received widespread industry recognition in the respective countries and regions.

For more information, please visit the website of Ubitus:

Media Contact

Ubitus Inc.
TEL: +886-2-2717-6123

About KT Corporation

KT Corporation is a South Korean integrated wired/wireless telecommunication service provider. KT focuses on information and communications business, and it has the largest portion of the South Korean local telephone and high-speed Internet market. Originally founded in 1981 as a public corporation, KT actively led Korea’s transition to the information era and played a key role in promoting the growth of Korea into a globally recognized IT superpower.

Logo –

ClearTV Media and Branded Cities partner with Royce Clayton’s Musiq Locker to bring sports and music content to Times Square’s spectacular digital screens

BURBANK, California and NEW YORK, Jan. 5, 2015 /PRNewswire/ — ClearTV Media (CLTV:F) and Branded Cities have developed a prominent partnership with Royce Clayton’s Musiq Locker to amplify content across the Branded Cities digital-out-of-home network of iconic media destinations in New York, Los Angeles, Las Vegas, Denver and Phoenix. Branded Cities Network is a digital spectacular media company with iconic signage in iconic destinations throughout the United States. The Branded Cities Network promotes national and local brands throughout its network of spectacular, static and digital sign displays.

ClearTV and Musiq Locker

ClearTV and Musiq Locker

ClearTV Media is a world leading media and Entertainment Company, creating, developing, producing and distributing entertainment, news and information to a global audience. ClearTV Media owns and operates a valuable portfolio of television platforms that deliver highly relevant content to targeted audiences inside airports, healthcare facilities and throughout the entire social media landscape. 

Musiq Locker is a brainchild of former MLB All-Star Royce Clayton. Musiq Locker brings sports and music content together like never seen before. Musiq Locker will produce unique and custom walk up songs to many of the top MLB players across the country, teaming up the player with their favorite artist.

“I am beyond thrilled to be able to bring these two major genres together, music and sports, like no one has before,” says Musiq Locker’s founder Royce Clayton.“The partnership we have formed with both TVChannels4U and Branded Cities will only grow as the hunger for great custom content keeps growing with digital audiences across the world.”

With this partnership, ClearTV Media, Branded Cities and Musiq Locker are taking TV everywhere to the next level with the dynamic TVChannels4U platform — the kick off for this unique partnership took place during the 2014 MLB World Series with trivia pieces centered around music and baseball. These pieces, including a trivia piece about Michael Jackson’s love of baseball were viewed by the Times Square audience of 1.5 million per day. Musiq Locker and ClearTV Media are in talks with several other sports leagues and sports organizations to expand this thrilling partnership in 2015 and beyond.

Tim Kennedy, President of Branded Cities East said, “We are thrilled to continue the expansion of the custom video content platform to our network of full motion digital spectaculars in multiple markets. These programs with ClearTV Media and Musiq Locker clearly demonstrate our ability to deliver unique/interesting content to our audiences.  The platform also offers great exposure and engagement opportunities for our brand partners as they seek to expand their sponsored video content investments beyond the traditional online digital screen.”

The ClearTV Media, Branded Cities and Musiq Locker partnership will offer brand partners new and innovative content sponsorship opportunities distributed across Branded Cities digital screens as well as online and through social and mobile outlets.  The partnership answers the dramatic shift brands now place on rich, high-quality content playing throughout the consumer’s daily digital life.

“With the traditional television fading to the back ground of the mainstream viewer, we are pleased to be able to bring high quality content to both our audience on the go as well as the advertiser, whether it be on line or on digital screens across the US,” states Jonna Birgans, VP of Programming, ClearTV Media.

About ClearTV Media
The ClearTV Media promise delivers customized TV stations to dynamic Away-From-Home environments bringing airports, healthcare facilities, retailers, and hotel and resorts a new marketing tool that will target, reach and engage a world on-the-go.  ClearTV Media has the power to connect with upscale demographics in ways never before imagined by infusing premium content with social media technology. ClearTV Media recently launched TVChannels4u drives talent and customized programming in the new age of the always-on-demand, mobile and social world. We create, produce and curate the best in Social TV – providing established and new producers with the tools to make and distribute TV series’ like never before. TVCHANNELS4U entertains and engages viewers with original TV programming from a wide variety of genres – Comedy, Drama, News, Sports, Education and Information.  To learn more please visit or or Twitter @TVChannels4u

About Branded Cities Network
Branded Cities Network, a subsidiary of EL Media, is a fully integrated, digital, spectacular signage media company. BCN’s current U.S. platform includes Los Angeles, Las Vegas, Phoenix, Denver, Minneapolis and New York. EL Media’s current platform, through its Canadian joint venture with Clear Channel Outdoor, includes Toronto, Vancouver, Montreal, Ottawa, Edmonton and Winnipeg. BCN is owned by The Ellman Companies and Cantor Fitzgerald. Ellman is a privately-owned media, real estate and investments company founded in 1972 with diverse ownership interests throughout the U.S., Canada and the Caribbean. For more information visit: or Cantor Fitzgerald is a preeminent capital markets investment bank serving more than 5,000 institutional clients around the world, recognized for its strengths in fixed income and equity capital markets, investment banking services, prime brokerage and commercial real estate financing. For more information please visit:

About Musiq Locker
Established in 2013, MUSIQ Locker is a joint venture between former MLB player Royce Clayton and Kevin Hall, EVP of Creative at Rondor records, a division of Universal Music Group.

MUSIQ Locker helps players build their personal brand by matching them with well-known music artists to create their own walk-up song, which can be sponsored by consumer brands. Walk-up songs are utilized through the ballpark and during TV & radio broadcasts, reaching millions of fans. MUSIQ Locker owns the rights to produce over 700 MLB player songs.

Ronnie Seidel

Photo –

Lilly Announces Diabetes Research Partnership with University of Surrey

– The five-year collaboration with the UK public research university will focus on health outcomes for people with type 2 diabetes

INDIANAPOLIS, Dec. 22, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease.

Using real-world evidence (routine data gathered from patients undergoing diabetes treatments), Lilly and the University of Surrey will focus on developing answers to commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis.

“Living with diabetes is a long and involved journey for patients and their caregivers,” said Brad Curtis, Ph.D., principal research scientist, Lilly Diabetes medical affairs. “It’s important for clinicians to understand each step of that journey so patients might have a better chance to reach optimal outcomes. We are honored to collaborate with the University of Surrey on this important project.”

“Diabetes is a complex condition to manage, requiring each patient to be treated and supported in a variety of ways,” said Professor Simon de Lusignan of the University of Surrey. “Our research uses routine data to help busy clinicians incorporate innovation into routine practice, focusing on those diseases that pose highest risk. By understanding how effectively individual care plans work we can learn more about how to improve and enhance diabetes care broadly. Our aim is to ensure that those suffering with the disease receive treatments that allow them to continue living their lives in the fullest sense, with effective support in place.”

Initially the Lilly-Surrey collaboration will focus on some key questions:

  • Adherence to therapy: Why do some people follow their diabetes treatment plan while others do not? What role do healthcare providers play in improving adherence rates? What are the barriers and the long-term effects for those who do not adhere to their treatment?
  • Triggers for initiation of injectable therapy: People with type 2 diabetes often transition to different therapies in an effort to gain greater control of the disease. These transitions could include moving from an oral treatment to an injectable medicine, such as a glucagon-like peptide 1 receptor agonist (GLP-1) or insulin. Which treatment would be best? What factors influence a health-care professional’s decision in choosing an injectable option? What factors influence the patient’s acceptance of that decision?
  • Understanding perspectives of both the patient and healthcare professional: How can health-care providers gain a better understanding of the patient’s journey? What are the key questions they and the patient can ask each other? Can real-world perspectives increase understanding of why some patients accept transition from orals to injectables to insulin, while others are less enthusiastic?

Diabetes remains one of society’s most prevalent diseases. More than 387 million people worldwide have type 1 and type 2 diabetes.1 Type 2 diabetes is the most common, accounting for an estimated 90 to 95 percent of all diabetes cases. Diabetes is a chronic disease that occurs when the body either does not properly produce, or use, the hormone insulin. 1

About the University of Surrey
The University of Surrey is one of the UK’s leading professional, scientific and technological universities with a world class research profile and a reputation for excellence in teaching and research. Ground-breaking research at the University is bringing direct benefit to all spheres of life – helping industry to maintain its competitive edge and creating improvements in the areas of health, medicine, space science, the environment, communications, defense and social policy. Programs in science and technology have gained widespread recognition and it also boasts flourishing programs in dance and music, social sciences, management and languages and law.

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at, @LillyHealth on Twitter and P-LLY

1. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. .

Refer to: Candace Johnson, +1-317-755-9143,
Amy Sutton, +44 (0) 1483 686141,

Logo –

Sorrento and Conkwest Announce Exclusive Global Collaboration

— Developing Next Generation Cancer Immunotherapy with “Off-the-Shelf” Chimeric Antigen Receptor-Tumor Attacking Natural Killer (CAR-TNK™) Cell Lines

SAN DIEGO and CARDIFF-BY-THE-SEA, Calif., Dec. 19, 2014 /PRNewswire/ — Sorrento Therapeutics, Inc. (NASDAQ: SRNE;  Sorrento), an oncology company developing new treatments for cancer and associated pain, and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast® (NK-92™), a Natural Killer (NK) cell-line based therapy, announced today that the companies have entered into a definitive agreement to jointly develop next generation CAR-TNK™ (pronounced as “Car-Tank”) immunotherapies for the treatment of cancer. The CAR-TNK technology platform combines Conkwest’s proprietary Neukoplast cell line with Sorrento’s proprietary G-MAB® fully human antibody technology and CAR designs to further enhance the potency and targeting of Neukoplast. Under the terms of the agreement, Sorrento and Conkwest will establish an exclusive global strategic collaboration focused on accelerating the development of CAR-TNKs for the treatment of hematological malignancies as well as solid tumors. Both companies will jointly own and share development costs and revenues from any developed CAR-TNK products. As part of the transaction, Sorrento will make a $9 million strategic equity investment in Conkwest and provide $2 million in research credit payments towards the development of novel CAR-TNK cell lines.

Adoptive immunotherapy is widely regarded as one of the most impactful and innovative anti-cancer therapy breakthroughs. To date, T-cell based therapies, like CAR-T, have shown the most promise in select hematologic cancers, especially B-cell malignancies such as acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). They have also demonstrated outstanding therapeutic impact, including a high percentage of complete responses (CRs) in leukemia patients using CD19-CAR-T cells. While the clinical results seen have been promising, CAR-T therapies have been associated with some concerning side effects, especially potentially fatal cytokine-release syndrome that is mediated by interleukin-6 (IL-6) released from the T-cells and characterized by high fevers and sudden drops in blood pressure. Afflicted patients often require aggressive support in an intensive care unit setting.  Additionally, most current CAR-T approaches rely upon patient derived T-cells, which require individualized processing, and are thus challenging with regard to commercial scalability, quality control, and consistency. Furthermore, this process relies on the ability to obtain sufficient numbers of the patients’ own immune T-cells to make adequate doses of CAR-T cells.

The “off-the-shelf” CAR-TNK approach will utilize Conkwest’s bioreactor-grown NK-92 cell line, Neukoplast, as the immune effector cells.  Among the many features that distinguish Neukoplast from patient derived T-cells are the lack of IL-6 expression (the most common mediator of cytokine release syndrome), an innate capability of destroying a broad range of cancer cells as well as cancer stem cells, and scalability with batch-to-batch consistency. These Neukoplast cells can be re-engineered in a virus-free process to express surface receptors using Sorrento’s G-MAB library to yield a stable line of effector cells that recognize and target specific antigens on tumor cells. The CAR-TNK cells can also be generated and produced in large quantities, thereby obviating the need for expensive, decentralized ‘biologistics’- a critical drawback of current CAR-T and dendritic cell therapies.

“We are extremely pleased with this strategic collaboration with Conkwest,” said Dr. Henry Ji, President and CEO of Sorrento. “With Sorrento’s expertise in antibody technology and diverse portfolio of fully human antibodies obtained from the G-MAB library, we believe we will be able to generate an army of stable CAR-TNK cell-lines, including but not limited to CD19-CAR-TNK™, PDL1-CAR-TNK™, PSMA-CAR-TNK™, and CD123-CAR-TNK™. It is our goal to rapidly move several of our CAR-TNK cell lines into the clinic to offer patients suffering from hematological malignancies and solid tumors an innovative immunotherapy to fight their cancers.”

“Conkwest has made important strides in establishing the safety and anti-cancer activity of Neukoplast in both pre-clinical and clinical phase I trials,” said Dr. Barry Simon, President and CEO of Conkwest. “We have also unlocked the potential of CAR-modified Neukoplast cells in preclinical models. By drawing from Sorrento’s treasure trove of CARs derived from their G-MAB library, we believe this partnership will enable us to realize an important part of our vision of designing and commercializing next generation Neukoplast products re-engineered to express one or more proprietary CARs that would matter most to disease outcomes. We are very excited about this opportunity in joining our resources and talent and look forward to working with the Sorrento team on this next generation of cancer immunotherapies.” 

About Sorrento Therapeutics, Inc. 

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento’s most advanced asset Cynviloq™, the next-generation nanoparticle paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated ADC platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento’s strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bi-specific therapeutic antibodies, ADCs and CAR-TNK cell-lines.

About Conkwest 

Conkwest is an innovative immuno-oncology company that is developing and commercializing a portfolio of highly potent and selective cellular therapies for the treatment of cancers and serious viral infections. Conkwest’s products are based on its proprietary cancer-killing cell line, Neukoplast (also known as NK-92) – the only known cell line that can be commercialized as a direct, scalable, off-the-shelf, cancer-killing product. Neukoplast recognizes, binds and directly kills cells expressing stress ligands such as LFA-3, Heparin Sulfate, ICAM-1 and other stress induced proteins commonly found on cancers and virally infected cells.  It has demonstrated broad anti-cancer activity both in vitro and in human clinical trials while sparing patients from the serious adverse reactions often seen with CAR-T based therapies. Cancer patients have been treated in phase I clinical trials at RUSH University, Frankfurt AM Main, Princess Margaret Hospital and University of Pittsburgh Cancer Institute. Preparations for the first U.S. phase II trial in Merkel Cell Carcinoma are currently underway.  Conkwest’s universal antibody-targeted CD16-Neukoplast, a re-engineered product which expresses both the high-affinity version of FcgammaR3 (CD16) and ER-IL2 to efficiently target therapeutic monoclonal antibodies such as Rituxan®, Herceptin® and Erbitux®, is presently in the preclinical stage of development.  Conkwest also commercializes Neukopanel®, an NK-92 based bioassay panel for the screening and qualification of therapeutic monoclonal antibody products, with revenue bearing licenses to many well-known large pharma and biotechnology companies.

Forward-Looking Statements

This press release contains forward-looking statements related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the expected achievements of the joint venture with Conkwest; the ability to develop proprietary stable CAR-TNK cell lines; anticipated timing for moving CAR-TNK cell lines into the clinic; Sorrento’s Cynviloq registrational trial; Sorrento’s advances made in developing RTX and human monoclonal antibodies using its proprietary G-MAB fully human antibody technology, if any; and other matters that are described in Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2013, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.  

G-MAB, TNK, CAR-TNK, CD19-CAR-TNK, PDL1-CAR-TNK, PSMA-CAR-TNK, and CD123-CAR-TNK are trademarks owned by Sorrento Therapeutics, Inc.

Neukoplast, Neukopanel and NK-92 are trademarks owned by Conkwest, Inc.